With Vioxx , researchers had been warning about the drug 's possible cardiovascular risks since 2000 , only a year after it was approved by the FDA .The FDA safety officer in charge of the report , David Graham , concluded that Vioxx posed much greater cardiovascular risk than the other major drug in its class , Celebrex .The FDA said last week after Vioxx was withdrawn that the problems were unique to that drug .By contrast , Vioxx made $ 2.5 billion for Merck last year .